In diet-induced obese mice, the mitochondria-targeted senolytic agent MitoTam reduced pulmonary senescence burden, suppressed pro-fibrotic gene expression (GDF15, FGF2, TGFβ, endothelin-1/EDN1), curtailed myofibroblast accumulation, and alleviated lung hypoxia. Parallel findings in class III obesity patients undergoing laparoscopic sleeve gastrectomy showed that substantial weight loss independently reduced adipose senescence and circulating EDN1, reinforcing a systemic adipose-to-lung signaling axis.
The mechanistic thread here is compelling: senescent cells in visceral and subcutaneous adipose tissue appear to drive pulmonary fibrosis not just locally but through endocrine mediators—particularly EDN1, a potent vasoconstrictor with known pro-fibrotic properties in the lung. This adipose-lung crosstalk reframes metabolic syndrome as a systemic senescence disorder with organ-distant consequences, an emerging perspective gaining traction since the landmark 2015 Kirkland senolytic papers.
MitoTam, which targets mitochondrial complex I to selectively eliminate senescent cells, offers a pharmacological angle where lifestyle intervention is insufficient or delayed. However, significant caveats apply: the mouse model, while metabolically relevant, cannot fully recapitulate human pulmonary fibrosis pathology, and the human arm is observational without a non-surgical control group. Effect sizes on actual lung function endpoints—FVC, DLCO—are absent. That said, the convergence of mouse pharmacology and human bariatric data around the same molecular signature (EDN1 reduction) elevates this beyond typical animal-only mechanistic work. Categorically incremental-to-notable: it doesn't overturn existing paradigms but meaningfully advances the senescence-metabolic-pulmonary fibrosis triangle with a tractable therapeutic candidate.
